Nahid A. Qushmaq: Advancing Anticoagulation Through Factor XI/XIa Inhibition
Nahid A. Qushmaq, General Supervisor Assistant for Medical Support Services, Consultant Adult Hematology of Thrombosis and Hemostasis, Head Of Research and Development Department at King Abdullah Medical Complex – Jeddah, shared a post on LinkedIn:
“One of the most valuable sessions I attended at ISTH 2026 was ‘Emerging Therapies in Thrombosis: Factor XI/XIa Inhibitors’, delivered by Dr. Jeffrey Weitz.
The session provided an excellent overview of the evolving role of FXI/FXIa inhibition in thrombosis prevention and highlighted the exciting potential of these novel agents to reduce thrombotic events while minimizing bleeding risk, making it one of the most promising next-generation anticoagulant strategies.
An insightful and thought-provoking session that reinforces how rapidly the field of thrombosis is advancing.”
Stay updates with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI